T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.95% |
| 2 | Consumer Discretionary | 13.63% |
| 3 | Financials | 12.8% |
| 4 | Industrials | 12.27% |
| 5 | Technology | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACOR
1301
DELISTED
Acorda Therapeutics
ACOR
| $10.4M | ﹤0.01% |
2,569
-5
| -0.2% | -$20.4K |
|
|
BBNK
1302
DELISTED
BRIDGE CAPITAL HOLDINGS
BBNK
| $10.4M | ﹤0.01% |
427,861
-48,300
| -10% | -$1.11M |
|
|
DNR
1303
DELISTED
Denbury Resources, Inc.
DNR
| $10.3M | ﹤0.01% |
560,377
| – | – |
|
|
DST
1304
DELISTED
DST Systems Inc.
DST
| $10.3M | ﹤0.01% |
224,326
+32,200
| +17% | +$1.48M |
|
|
SLH
1305
DELISTED
SOLERA HOLDINGS, INC. COM
SLH
| $10.3M | ﹤0.01% |
153,550
-1,700
| -1% | -$111K |
|
1306
Hormel Foods
HRL
$13.4B
| $10.3M | ﹤0.01% |
416,696
| – | – |
|
|
RVBD
1307
DELISTED
RIVERBED TECHNOLOGY, INC COM
RVBD
| $10.3M | ﹤0.01% |
496,935
+70,500
| +17% | +$1.39M |
|
|
BCIC
1308
BCP Investment Corp
BCIC
$95.6M
| $10.2M | ﹤0.01% |
120,242
-1,110
| -0.9% | -$89.6K |
|
1309
Virtus Investment Partners
VRTS
$1.12B
| $10.1M | ﹤0.01% |
47,924
+3,300
| +7% | +$622K |
|
|
NFX
1310
DELISTED
Newfield Exploration
NFX
| $10M | ﹤0.01% |
227,210
-919,255
| -80% | -$33M |
|
|
QVCGA
1311
DELISTED
QVC Group Inc Series A
QVCGA
| $10M | ﹤0.01% |
8,308
-23,129
| -74% | -$27.6M |
|
|
TAST
1312
DELISTED
Carrols Restaurant Group, Inc.
TAST
| $10M | ﹤0.01% |
1,404,677
+761,100
| +118% | +$5.27M |
|
|
NMBL
1313
DELISTED
Nimble Storage, Inc.
NMBL
| $9.95M | ﹤0.01% |
+323,798
| New | +$9.08M |
|
|
ENDP
1314
DELISTED
Endo International plc
ENDP
| $9.94M | ﹤0.01% |
141,898
+97,906
| +223% | +$6.55M |
|
1315
Pinnacle West Capital
PNW
$12.2B
| $9.92M | ﹤0.01% |
171,580
+2,300
| +1% | +$127K |
|
|
POLY
1316
DELISTED
Plantronics, Inc.
POLY
| $9.9M | ﹤0.01% |
206,050
+13,900
| +7% | +$619K |
|
1317
Lexicon Pharmaceuticals
LXRX
$1.04B
| $9.86M | ﹤0.01% |
874,870
-47,229
| -5% | -$507K |
|
1318
Precigen
PGEN
$2.32B
| $9.86M | ﹤0.01% |
410,372
-5,127
| -1% | -$104K |
|
|
CPHD
1319
DELISTED
Cepheid Inc
CPHD
| $9.83M | ﹤0.01% |
205,120
+14,004
| +7% | +$635K |
|
|
ECHO
1320
EchoStar
ECHO
$26.6B
| $9.82M | ﹤0.01% |
228,937
+118,464
| +107% | +$4.72M |
|
|
AIG.WS
1321
DELISTED
American International Group, Inc.
AIG.WS
| $9.81M | ﹤0.01% |
368,700
| – | – |
|
1322
Forestar Group
FOR
$1.49B
| $9.71M | ﹤0.01% |
508,440
+497,740
| +4,652% | +$8.84M |
|
|
TEG
1323
DELISTED
INTEGRYS ENERGY GROUP INC COM (USA)
TEG
| $9.6M | ﹤0.01% |
134,924
+1,125
| +0.8% | +$67.6K |
|
1324
MarketAxess Holdings
MKTX
$5.72B
| $9.54M | ﹤0.01% |
176,400
-43,700
| -20% | -$2.39M |
|
1325
Teradata
TDC
$2.57B
| $9.53M | ﹤0.01% |
237,076
-11,100
| -4% | -$485K |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.